Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMT Bolus Dose-Response in Healthy Subjects
NCT05695495Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Jun 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial of DMT in major depressive disorder (MDD) (2 arms), sponsored by University Hospital Basel. Primary endpoints: Altered States of Consciousness Profile and Subjective Effect Ratings. Started Jun 2024; status: completed.
02
Drugs
DMT
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05695495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05695495.